Ticker Attention Investors: Note: The depositories (CDSL/NSDL), in coordination with SEBI, have upgraded their investor mobile applications to provide a consolidated view of investors’ holdings in securities markets. CDSL: MyEasiApp | NSDL: Speede App Beware of fraudulent Calls, SMS, Emails, WhatsApp & Telegram messages assuring high returns and / or enticing you to invest money in the name of Aditya Birla Money by installing fake App from spurious links. You can download our Elevate App only from Google Play Store or Apple App Store or login to Elevate Web portal. Click Here to know more.

Aditya Birla Money Limited

Aditya Birla Money Limited

Sanofi India Ltd

Symbol : SANOFI | BSE Code : 500674 | Sector : PHARMACEUTICALS - MULTINATIONAL

3,427.60-17.70 (-0.51%)
24-Apr-2026 | 12:00
Loading

Market Cap (₹ Cr.)

7,893.76
Today’s High / Low
3,481.00
3,419.00
52 Week High / Low
6,717.00
3,160.00
3,430.80-13.50 (-0.39%)
24-Apr-2026 | 12:00
Loading

Market Cap (₹ Cr.)

7,901.13
Today’s High / Low
3,475.00
3,419.20
52 Week High / Low
6,717.50
3,151.05
3,427.60-17.70 (-0.51%)
24-Apr-2026 | 12:00

Turnover (₹ Cr.)

45,929,091,787.50
Today’s High / Low
56,490
55,806.00
3,427.60-17.70 (-0.51%)
24-Apr-2026 | 12:00

Turnover (₹ Cr.)

1,881,127,134.25
Today’s High / Low
1,102
861.55
OVERVIEW
  • Open
  • 3,481.00
  • Prev. Close
  • 3,445.30
  • High
  • 3,481.00
  • Low
  • 3,419.00
  • Market Cap (₹ Cr.)
  • 7,893.76
  • 52 Week High
  • 6,717.00
  • 52 Week Low
  • 3,160.00
  • Traded Volume (Lacs)
  • 21,052
  • Traded Value (Cr)
  • Dividend Yield
  • 3.58
  • Face Value
  • 10.00
  • EPS
  • 150.41
  • P/E
  • 22.81
  • Beta (1 year)
  • 1.02
OVERVIEW
  • Open
  • 3,437.80
  • Prev. Close
  • 3,444.30
  • High
  • 3,475.00
  • Low
  • 3,419.20
  • Market Cap (₹ Cr.)
  • 7,901.13
  • 52 Week High
  • 6,717.50
  • 52 Week Low
  • 3,151.05
  • Traded Volume (Lacs)
  • 1,235
  • Traded Value (Cr)
  • Dividend Yield
  • 3.58
  • Face Value
  • 10.00
  • EPS
  • 150.41
  • P/E
  • 22.81
  • Beta (1 year)
OVERVIEW
  • Open
  • 56,401.00
  • Prev. Close
  • 56,344.20
  • High
  • 56,490
  • Low
  • 55,806.00
  • Strike Price
  • 0.00
  • Open Interest(Nos.)
  • 1,241,610.00
  • OI Change %
  • -19.81
  • Volume(Lacs)
  • -19.81
  • Lot Size
  • 30.00
  • Average Price
  • 56,084.70
  • OI Difference
  • -306,750.00
  • Previous OI
  • 1,548,360.00
OVERVIEW
  • Open
  • 866.90
  • Prev. Close
  • 801.25
  • High
  • 1,102
  • Low
  • 861.55
  • Strike Price
  • 24,950.00
  • Open Interest(Nos.)
  • 28,275.00
  • OI Change %
  • 7.41
  • Volume(Lacs)
  • 7.41
  • Lot Size
  • 65.00
  • Average Price
  • 963.35
  • OI Difference
  • 1,950.00
  • Previous OI
  • 26,325.00
LAST 5 DAYS

1 YEAR RETURN - UNDERPERFORMED THE SENSEX BY 43.85%

  • 25/04/2026 BSE
    -13.50(-0.39)
    Close Price: ₹ 3,430.80
    Volume: 1,235.00

    24-Apr-2026
  • 25/04/2026 BSE
    -57.10(-1.63)
    Close Price: ₹ 3,444.30
    Volume: 1,458.00

    23-Apr-2026
  • 25/04/2026 BSE
    -85.80(-2.39)
    Close Price: ₹ 3,501.40
    Volume: 1,633.00

    22-Apr-2026
  • 25/04/2026 BSE
    8.65(0.24)
    Close Price: ₹ 3,587.20
    Volume: 2,511.00

    21-Apr-2026
  • 25/04/2026 BSE
    18.75(0.53)
    Close Price: ₹ 3,578.55
    Volume: 4,087.00

    20-Apr-2026

1 YEAR RETURN - UNDERPERFORMED THE SENSEX BY 43.85%

  • Stock Absolute
  • -3.62
  • 5.57
  • -47.78
  • -42.75
  • -53.88
  • Returns
  • 1W
  • 1M
  • 1Y
  • 3Y
  • 5Y
  • Sensex Absolute
  • -2.33
  • 3.50
  • -3.93
  • 27.65
  • 58.44
NEWS

Sanofi India announces board meeting date

20-Apr-2026

No Data Available

Sanofi India will hold a meeting of the Board of Directors of the Company on 28 April 2026.

20
Apr

Sanofi India announces board meeting date



26
Feb

Board of Sanofi India recommends final dividend



26
Feb

Sanofi India standalone net profit declines 32.42% in the December 2025 quarter



FINANCIAL DATA

In Cr.

Dec 2025Dec 2024Dec 2023
SOURCES OF FUNDS :   
Share Capital 23.0023.0023.00
Reserves Total 726.20837.60992.50
Equity Share Warrants0.000.000.00
Equity Application Money0.000.000.00
Read More
Dec 2025Dec 2024Dec 2023
INCOME :   
Sales Turnover 1,837.402,013.202,851.10
Excise Duty0.000.000.00
Net Sales1,837.402,013.202,851.10
Other Income 19.70116.3083.10
Read More
ParticularsDec 2025Sep 2025Jun 2025
Gross Sales 419.80475.40406.30
Excise Duty 000
Net Sales 419.80475.40406.30
Other Operating Income 000
Other Income  2.804.908.70
Read More
Category No. Of Shares Percentage (%)
Total Foreign 1525826 6.63
Total Institutions 4865963 21.13
Total Govt Holding 0 0.00
Total Non Promoter Corporate Holding 224906 0.98
Total Promoters 13909587 60.40
Total Public & others 2,504,340.00 10.87
Total 100.00 100.00
Read More
CORPORATE ACTIONS
Record Date Ex-Bonus Date Ratio
nodata
No Data Available!!!
Read More
Record Date Split Date Face Value Before Face Value After
nodata
No Data Available!!!
Read More
Read More
ANNOUNCEMENT DATE EX DIVIDEND DATE DIVIDEND (%) DIVIDEND TYPE
25-02-2026 22-04-2026 480 Final
29-10-2025 07-11-2025 750 Interim
27-02-2025 25-04-2025 1170 Final
23-02-2024 03-05-2024 1170 Final
23-02-2024 07-03-2024 500 Interim
PREMIUM (₹) RATIO RECORD DATE EX RIGHTS DATE
nodata
No Data Available!!!
Read More
Read More
FROM DATE EX TO DATE AGENDA
29-04-2026 NA Convening of the Seventieth An...
28-04-2026 NA Sanofi India Ltd has informed ...
23-04-2026 29-04-2026 In the above context, the Regi...
22-04-2026 NA Record Date For Final Dividend...
22-04-2026 NA 480% Final Dividend
COMPANY INFO

Sanofi India Limited, was initially incorporated as 'Aventis Pharma Limited' in May, 1956. The Company changed its name from Aventis Pharma Limited to Sanofi India Limited on May 11, 2012. The Company is amongst the leading multinational companies (MNCs) in the Indian Pharmaceutical Market. The Company is primarily engaged in the business of manufacturing and trading of drugs and pharmaceuticals. It has its own manufacturing facility at Goa. It sell products through independent distributors primarily in India.

Sanofi India's products viz. Lantus, Combiflam, Amaryl and Allegra feature in the top 100 pharmaceutical brands in India. The Company has its own manufacturing facility at Goa and Ankleshwar, Gujarat. It sells products through independent distributors primarily in India. Sanofi, one of the world's leading pharmaceutical companies, and its 100% subsidiary, Hoechst GmbH, are the major shareholders of Sanofi India Limited and together hold 60.37% of its paid-up share capital.

During the year 1997-98, the Joint Venture Company, Chiron Behring Vaccines Pvt Ltd started to manufacture anti-rabbies vaccine 'Rabipur'. Roussel India Ltd was amalgamated with the Company with effect from April 1, 1997 and Hoechst Nepal (Pvt) Ltd, a subsidiary Company in Nepal was wound up during the year. During the year 1999-2000, Aventis launched anti-diabetic Amaryl broad spectrum anti-infective Tavanic and line extension of anti-hypertensive Cardace H.

In the year 2001, Rhone-Poulenc Rorer (India) Pvt Ltd was amalgamated with the company. The company name was changed from Hoechst Marion Roussel Ltd to Aventis Pharma Ltd with effect from July 11 2001. In July 2003. the company launched Lantus, the world's first and only once a day insulin and in December 2003, Actonel, designed for the treatment of osteoporosis was launched.

In the year 2004, the company came under the control of Sanofi-Synthelabo, now called sanofi-aventis which acquired indirect control 50.1% of the com

Read More
Get Free Demat Account
Captcha Image